Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial with Safety Run-in of MEK Inhibitor AS703026 in Poor-Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies
2009-010866-49Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pimasertib in acute myeloid leukemia (AML) and hematopoietic malignancies, sponsored by Merck Serono. Primary endpoint: Safety and tolerability in safety run-in part. Started Apr 2009; status: completed.
02
Drugs
pimasertib
03
Conditions
acute myeloid leukemia (AML)hematopoietic malignancies
Beyond the preview
Go deeper on 2009-010866-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010866-49.